Skip to main content
IBRX
NASDAQ Life Sciences

UAE Approves ANKTIVA for Bladder and Lung Cancer, First Broad NMIBC Label

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$6.86
Mkt Cap
$7.153B
52W Low
$1.95
52W High
$12.43
52W Position info
252% above low
Off High info
45% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

IBRX has more than doubled off its 52-week low of $1.95.

Summary

ImmunityBio secured UAE marketing authorization for ANKTIVA in two indications: BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and metastatic non-small cell lung cancer (NSCLC). The NMIBC approval is the first globally to cover the full disease spectrum, including papillary-only tumors without CIS, addressing a significant unmet need. The NSCLC indication targets checkpoint-refractory patients, a population with limited options. This is the fifth regulatory jurisdiction, expanding ANKTIVA's reach to 34 countries. The news follows strong Q1 revenue growth and a recent BCG supply agreement, reinforcing commercial momentum. With a market cap around $7.2B, this regulatory win could open new revenue streams and strengthen the global commercial case.

Updates

  1. · Benzinga — The UAE approval includes a 71% complete response rate in CIS patients and 58.2% disease-free survival at 12 months in papillary-only patients. Shares rose 5.5%.

At the time of this announcement, IBRX was trading at $6.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2B. The 52-week trading range was $1.95 to $12.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

IBRX - Latest Insights

IBRX
Nov 09, 2026, 7:52 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.59
Real-time Price: $6.53 info
Change: -$1.06 (-14%) info
Market Cap: $6.989B info
IBRX
Nov 09, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.09
Real-time Price: $6.53 info
Change: -$1.56 (-19%) info
Market Cap: $6.989B info
IBRX
Nov 09, 2026, 7:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.84
Real-time Price: $6.53 info
Change: -$2.31 (-26%) info
Market Cap: $6.989B info
IBRX
Nov 09, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.76
Real-time Price: $6.53 info
Change: -$2.23 (-25%) info
Market Cap: $6.989B info
IBRX
Oct 16, 2026, 11:49 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.42
Real-time Price: $6.53 info
Change: -$2.89 (-31%) info
Market Cap: $6.989B info